Orgenesis Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 80

Employees

  • Stock Symbol
  • ORGS

Stock Symbol

  • Investments
  • 16

  • Share Price
  • $0.26
  • (As of Thursday Closing)

Orgenesis General Information

Description

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.

Contact Information

Formerly Known As
Business Outsourcing Service, Business Outsourcing Service, Inc.
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 20271 Goldenrod Lane
  • Germantown, MD 20876
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OTCM
Corporate Office
  • 20271 Goldenrod Lane
  • Germantown, MD 20876
  • United States

Orgenesis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orgenesis Stock Performance

As of 19-Nov-2026, Orgenesis’s stock price is $0.26. Its current market cap is $2.6M with 9.8M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.26 $0.02 $2.6M 9.8M 1.55K

Orgenesis Financials Summary

As of 31-Dec-2024, Orgenesis has a trailing 12-month revenue of $1.03M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 26,831 26,831 37,655 75,536
Revenue 1,035 1,035 530 36,025
EBITDA (43,091) (43,091) (60,718) (8,158)
Net Income (48,165) (48,165) (55,361) (14,889)
Total Assets 1,351 1,351 14,552 90,928
Total Debt 18,259 18,259 22,621 20,272
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Orgenesis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Orgenesis‘s full profile, request access.

Request a free trial

Orgenesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologo
Drug Discovery
Germantown, MD
80 As of 2025

San Ramon, CA
 

Mississauga, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Orgenesis Competitors (18)

One of Orgenesis’s 18 competitors is Histogen, a Formerly VC-backed company based in San Ramon, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Histogen Formerly VC-backed San Ramon, CA
Sernova Biotherapeutics Corporation Mississauga, Canada
Regenerative Medical Solutions Venture Capital-Backed Madison, WI
Treefrog Therapeutics Venture Capital-Backed Pessac, France
PeproTech Corporate Backed or Acquired Cranbury, NJ
You’re viewing 5 of 18 competitors. Get the full list »

Orgenesis Patents

Orgenesis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024226832-A1 Ribonucleases for treating viral infections Inactive 25-Apr-2023
EP-4680395-A1 Systems and methods for bio-manufacturing Pending 14-Mar-2023
EP-4680395-A4 Systems and methods for bio-manufacturing Pending 14-Mar-2023
WO-2024192060-A1 Systems and methods for bio-manufacturing Inactive 14-Mar-2023
US-20240131096-A1 Oncolytic virus combined with car t cells for anti-tumor therapy Pending 24-Oct-2022 A61K35/768
To view Orgenesis’s complete patent history, request access »

Orgenesis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orgenesis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Orgenesis‘s full profile, request access.

Request a free trial

Orgenesis Investments & Acquisitions (16)

Orgenesis’s most recent deal was a Merger/Acquisition with Neurocords. The deal was made on 06-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neurocords 06-Mar-2025 Merger/Acquisition Drug Discovery
Innovative Longevity & Wellness Services (Harley Street Healthcare / Orgenesis) 31-Dec-2024 Joint Venture Other Healthcare Services
Octomera 31-Jan-2024 Secondary Transaction - Private Biotechnology
MIDA Biotech 01-Feb-2022 Merger/Acquisition Biotechnology
Joint Venture (Orgenesis & Cure Therapeutics) 09-Dec-2020 Joint Venture Drug Discovery
You’re viewing 5 of 16 investments and acquisitions. Get the full list »

Orgenesis ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Orgenesis’s complete esg history, request access »

Orgenesis Exits (3)

Orgenesis’s most recent exit was on 31-Jan-2024 from Octomera. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Octomera 31-Jan-2024 Completed
Masthercell 29-Jun-2018 Completed
  • 3 buyers
Masthercell 27-Feb-2015 Merger/Acquisition Completed
To view Orgenesis’s complete exits history, request access »

Orgenesis Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Octomera Germantown, WI 2022
MIDA Biotech Leiden, Netherlands 2020

Orgenesis FAQs

  • When was Orgenesis founded?

    Orgenesis was founded in 2008.

  • Where is Orgenesis headquartered?

    Orgenesis is headquartered in Germantown, MD.

  • What is the size of Orgenesis?

    Orgenesis has 80 total employees.

  • What industry is Orgenesis in?

    Orgenesis’s primary industry is Drug Discovery.

  • Is Orgenesis a private or public company?

    Orgenesis is a Public company.

  • What is Orgenesis’s stock symbol?

    The ticker symbol for Orgenesis is ORGS.

  • What is the current stock price of Orgenesis?

    As of 19-Nov-2026 the stock price of Orgenesis is $0.26.

  • What is the current market cap of Orgenesis?

    The current market capitalization of Orgenesis is $2.6M.

  • What is Orgenesis’s current revenue?

    The trailing twelve month revenue for Orgenesis is $1.03M.

  • Who are Orgenesis’s competitors?

    Histogen, Sernova Biotherapeutics, Regenerative Medical Solutions, Treefrog Therapeutics, and PeproTech are some of the 18 competitors of Orgenesis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process